News NurExone Biologic Inc. Deutsche Boerse AG

Equities

J90

CA67059R1091

Real-time Estimate Tradegate Other stock markets 02:49:03 2024-07-18 am EDT			5-day change	1st Jan Change
0.478 ^EUR	-1.24%		+15.38%	+180.70%

Jul. 17	NurExone Biologic Inc. Announces Promising Preliminary Results in Optic Nerve Recovery Study of NurExone?s First Product ExoPTEN for Glaucoma	CI
Jun. 28	NurExone Biologic Inc. Announces Pre-Clinical Study to Explore the Potential of NurExone's Exosome-Based Therapies in Regenerating Damaged Optic Nerves	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma	Jul. 17	AQ
NurExone Biologic Inc. Announces Promising Preliminary Results in Optic Nerve Recovery Study of NurExone?s First Product ExoPTEN for Glaucoma	Jul. 17	CI
Updates from NurExone: Growth Conference Presentation and Website Relaunch	Jul. 05	AQ
NurExone Biologic Inc. Announces Pre-Clinical Study to Explore the Potential of NurExone's Exosome-Based Therapies in Regenerating Damaged Optic Nerves	Jun. 28	CI
NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market	Jun. 28	AQ
On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development	Jun. 21	AQ
NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application	Jun. 11	AQ
NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders	Jun. 04	AQ
NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials	May. 29	AQ
NurExone Biologic Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 29	CI
NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations	May. 17	AQ
NurExone Biologic Announces OTCQB Listing And DTC Eligibility	Apr. 25	MT
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility	Apr. 25	AQ
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine	Apr. 22	AQ
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine	Apr. 19	AQ
NurExone Biologic Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 02	CI
NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update	Apr. 02	AQ
Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise	Mar. 27	AQ
In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN	Mar. 22	AQ
NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence	Mar. 15	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News NurExone Biologic Inc. Deutsche Boerse AG

Equities

J90

CA67059R1091

Summary

Filters